Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. more
Time Frame | TCRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 15.78% | 2.3% | 1.73% |
1-Month Return | -2.45% | -1.77% | 3.44% |
3-Month Return | -13.74% | -6.07% | 7.02% |
6-Month Return | -45.42% | 2.45% | 13.38% |
1-Year Return | -7.92% | 12.17% | 32.25% |
3-Year Return | -39.77% | 10.46% | 29.27% |
5-Year Return | -54.57% | 46.4% | 90.61% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 1.08M | 10.14M | 13.54M | 21.05M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.15,"profit":true},{"date":"2021-12-31","value":48.18,"profit":true},{"date":"2022-12-31","value":64.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 519.00K | 20.58M | 3.33M | 5.14M | 88.15M | [{"date":"2019-12-31","value":0.59,"profit":true},{"date":"2020-12-31","value":23.34,"profit":true},{"date":"2021-12-31","value":3.78,"profit":true},{"date":"2022-12-31","value":5.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (519.00K) | (19.49M) | 6.81M | 8.40M | (67.10M) | [{"date":"2019-12-31","value":-6.18,"profit":false},{"date":"2020-12-31","value":-232.1,"profit":false},{"date":"2021-12-31","value":81.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-799.05,"profit":false}] |
Gross Margin | - | (1796.50%) | 67.18% | 62.05% | (318.80%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2674.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.35,"profit":true},{"date":"2023-12-31","value":-474.53,"profit":false}] |
Operating Expenses | 14.21M | 27.32M | 58.78M | 80.17M | 114.51M | [{"date":"2019-12-31","value":12.41,"profit":true},{"date":"2020-12-31","value":23.86,"profit":true},{"date":"2021-12-31","value":51.33,"profit":true},{"date":"2022-12-31","value":70.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (14.21M) | (26.23M) | (48.64M) | (66.64M) | (93.46M) | [{"date":"2019-12-31","value":-1421000000,"profit":false},{"date":"2020-12-31","value":-2623300000,"profit":false},{"date":"2021-12-31","value":-4864100000,"profit":false},{"date":"2022-12-31","value":-6663600000,"profit":false},{"date":"2023-12-31","value":-9345800000,"profit":false}] |
Total Non-Operating Income/Expense | 1.10M | 212.00K | 32.00K | 830.00K | 6.66M | [{"date":"2019-12-31","value":16.57,"profit":true},{"date":"2020-12-31","value":3.18,"profit":true},{"date":"2021-12-31","value":0.48,"profit":true},{"date":"2022-12-31","value":12.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (13.66M) | (26.13M) | (48.63M) | (66.22M) | (89.22M) | [{"date":"2019-12-31","value":-1365800000,"profit":false},{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4862500000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8921800000,"profit":false}] |
Income Taxes | (552.00K) | (106.00K) | 3.09M | (415.00K) | 5.19M | [{"date":"2019-12-31","value":-10.63,"profit":false},{"date":"2020-12-31","value":-2.04,"profit":false},{"date":"2021-12-31","value":59.53,"profit":true},{"date":"2022-12-31","value":-7.99,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (13.11M) | (26.02M) | (51.72M) | (65.81M) | (94.41M) | [{"date":"2019-12-31","value":-1310600000,"profit":false},{"date":"2020-12-31","value":-2602100000,"profit":false},{"date":"2021-12-31","value":-5171644200,"profit":false},{"date":"2022-12-31","value":-6580600000,"profit":false},{"date":"2023-12-31","value":-9441110500,"profit":false}] |
Income From Continuous Operations | (13.66M) | (26.13M) | (48.64M) | (66.22M) | (88.33M) | [{"date":"2019-12-31","value":-1365800000,"profit":false},{"date":"2020-12-31","value":-2612700000,"profit":false},{"date":"2021-12-31","value":-4864100000,"profit":false},{"date":"2022-12-31","value":-6622100000,"profit":false},{"date":"2023-12-31","value":-8832800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (13.11M) | (26.02M) | (48.63M) | (65.81M) | (89.22M) | [{"date":"2019-12-31","value":-1310600000,"profit":false},{"date":"2020-12-31","value":-2602100000,"profit":false},{"date":"2021-12-31","value":-4862500000,"profit":false},{"date":"2022-12-31","value":-6580600000,"profit":false},{"date":"2023-12-31","value":-8921800000,"profit":false}] |
EPS (Diluted) | - | - | (9.98) | (2.75) | (1.89) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-998,"profit":false},{"date":"2022-12-31","value":-275,"profit":false},{"date":"2023-12-31","value":-189,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TCRX | |
---|---|
Cash Ratio | 9.46 |
Current Ratio | 9.56 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TCRX | |
---|---|
ROA (LTM) | -23.36% |
ROE (LTM) | -55.92% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TCRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TCRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 26.45 |
P/B | 1.08 |
Price/FCF | NM |
EV/R | 7.14 |
EV/Ebitda | 0.39 |
Tscan Therapeutics Inc (TCRX) share price today is $4.77
Yes, Indians can buy shares of Tscan Therapeutics Inc (TCRX) on Vested. To buy Tscan Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TCRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tscan Therapeutics Inc (TCRX) via the Vested app. You can start investing in Tscan Therapeutics Inc (TCRX) with a minimum investment of $1.
You can invest in shares of Tscan Therapeutics Inc (TCRX) via Vested in three simple steps:
The 52-week high price of Tscan Therapeutics Inc (TCRX) is $9.69. The 52-week low price of Tscan Therapeutics Inc (TCRX) is $3.92.
The price-to-earnings (P/E) ratio of Tscan Therapeutics Inc (TCRX) is
The price-to-book (P/B) ratio of Tscan Therapeutics Inc (TCRX) is 1.08
The dividend yield of Tscan Therapeutics Inc (TCRX) is 0.00%
The market capitalization of Tscan Therapeutics Inc (TCRX) is $247.64M
The stock symbol (or ticker) of Tscan Therapeutics Inc is TCRX